---
trial_id: 646
discovery_date: 2022-04-15 12:12:54.129439
date: 2022-04-15 12:12:54.129439
title: "A Randomized, Open-label, Multi-center, Phase II Study of Asciminib Versus Best Available Therapy in Chinese Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors"
summary: |
  
link: 'https://www.novartis.com//clinicaltrials/study/nct04795427'
published_date: NaT
trial_source: Novartis
relevant: 
options:
  unlisted: false
---
